GRAIL to Unveil Key Cancer Detection Trial Results at ASCO 2026
Event summary
- GRAIL will present late-breaking data from NHS-Galleri and PATHFINDER 2 studies at the 2026 ASCO Annual Meeting.
- NHS-Galleri trial involved 142,000 participants, evaluating Galleri test in population screening.
- PATHFINDER 2 study included 32,000 participants, largest MCED interventional study in North America.
- Results aim to strengthen evidence for Galleri's clinical utility, performance, and safety.
The big picture
GRAIL's ASCO presentations come as multi-cancer early detection tests gain traction amid rising cancer incidence and screening gaps. The company aims to position Galleri as a complementary tool to existing screenings, targeting cancers without recommended tests. Success hinges on demonstrating real-world impact and cost-effectiveness in large-scale studies.
What we're watching
- Regulatory Pathway
- Whether PATHFINDER 2 results accelerate FDA approval for Galleri.
- Market Adoption
- The pace at which NHS-Galleri data influences global healthcare systems.
- Competitive Positioning
- How Galleri's performance metrics compare to emerging MCED technologies.
Related topics